SRNE Stock - Sorrento Therapeutics, Inc.
Unlock GoAI Insights for SRNE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $62.84M | $52.90M | $39.99M | $31.43M | $21.19M |
| Gross Profit | $29.39M | $39.87M | $30.05M | $19.20M | $11.12M |
| Gross Margin | 46.8% | 75.4% | 75.1% | 61.1% | 52.5% |
| Operating Income | $-504,315,000 | $-368,045,000 | $-201,526,000 | $-195,182,000 | $-129,477,000 |
| Net Income | $-572,843,000 | $-429,012,000 | $-298,461,000 | $-359,103,000 | $-203,540,000 |
| Net Margin | -911.6% | -810.9% | -746.4% | -1142.5% | -960.4% |
| EPS | $-1.37 | $-1.46 | $-1.30 | $-2.56 | $-1.92 |
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 2nd 2022 | Cantor Fitzgerald | Initiation | Overweight | $5 |
Earnings History & Surprises
SRNEEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Feb 11, 2025 | — | — | — | — |
Q4 2024 | Dec 27, 2024 | — | — | — | — |
Q3 2024 | Aug 16, 2024 | — | — | — | — |
Q2 2024 | May 20, 2024 | — | — | — | — |
Q1 2024 | Feb 28, 2024 | $-0.09 | — | — | — |
Q4 2023 | Nov 3, 2023 | $-0.15 | — | — | — |
Q3 2023 | Aug 12, 2023 | $-0.15 | $-0.17 | -15.1% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.16 | $-0.26 | -60.7% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-0.19 | $-0.34 | -79.8% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.25 | $-0.20 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.23 | $-0.31 | -34.8% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.25 | $-0.12 | +52.0% | ✓ BEAT |
Q1 2022 | Mar 11, 2022 | $-0.29 | $-0.47 | -62.1% | ✗ MISS |
Q4 2021 | Nov 5, 2021 | $-0.21 | $-0.40 | -90.5% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $-0.20 | $-0.33 | -65.0% | ✗ MISS |
Q2 2021 | May 5, 2021 | $0.38 | $0.01 | -97.4% | ✗ MISS |
Q1 2021 | Feb 19, 2021 | $-0.23 | $-0.27 | -17.4% | ✗ MISS |
Q4 2020 | Nov 6, 2020 | $-0.25 | $-0.33 | -32.0% | ✗ MISS |
Q3 2020 | Aug 4, 2020 | $-0.24 | $-0.22 | +8.3% | ✓ BEAT |
Q2 2020 | May 11, 2020 | $-0.20 | $-0.26 | -30.0% | ✗ MISS |
Latest News
Frequently Asked Questions about SRNE
What is SRNE's current stock price?
What is the analyst price target for SRNE?
What sector is Sorrento Therapeutics, Inc. in?
What is SRNE's market cap?
Does SRNE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SRNE for comparison